Postmenopausal hormone use, screening, and breast cancer: Characterization and control of a bias

Epidemiology

Volumn 12, Issue 4, 2001, Pages 429-438

  Joffe, Marshall M ^a,c   Byrne, Celia ^a   Colditz, Graham A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c 602 Blockley Hall ^*  (United States)

Author keywords

Bias; Breast neoplasms; Causality; Epidemiologic methods; Mammography; Postmenopausal hormone replacement

Indexed keywords

ESTROGEN DERIVATIVE; PROGESTERONE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED STUDY; DRUG USE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; POSTMENOPAUSE; REPRODUCIBILITY OF RESULTS;

EID: 0034990708     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-200107000-00013     Document Type: Article

References (32)

1. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
2. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women
3. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
4. Restriction as a method for reducing bias in the estimation of direct effects
5. Reproducibility and validity of self-reported menopausal status in a prospective cohort of women
6. Screening for cancer of the breast
7. Causal diagrams for epidemiologic research
8. Causal diagrams for empirical research
9. National Institutes of Health Consensus Development Statement: Breast cancer screening for women ages 40-49
10. Identifiability and exchangeability for direct and indirect effects
11. Approaches to the analysis of case-control studies of the efficacy of screening for cancer
12. Identifiability, exchangeability, and epidemiological confounding
13. Statistical aspects of the analysis of data from retrospective studies of disease
14. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk
15. Bias in breast cancer analyses due to error in age at menopause
16. Randomized study of mammography screening: Preliminary report on mortality in the Stockholm trial
17. The Stockholm breast cancer screening trial: 5-year results and stage at discovery
18. Canadian national breast screening study. 1. Breast cancer detection and death rates among women aged 40 to 49 years
19. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
20. Conjugated estrogens and fibrocystic breast disease
21. Estrogen replacement therapy and fibrocystic breast disease in postmenopausal women
22. Estrogen replacement therapy and benign breast disease
23. An analysis of detection bias and proposed corrections in the study of estrogens and endometrial cancer
24. Efficacy of screening mammography: A meta-analysis
25. Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern
26. Surrogate endpoints in clinical trials: Definition and operational criteria
27. Effect modification and the limits of biological inference from epidemiologic data
28. Conceptual problems in the definition and interpretation of attributable fractions